Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Apr;13(2):77-84.
doi: 10.1007/s11904-016-0304-1.

How to Define the Latent Reservoir: Tools of the Trade

Kirston M Barton  1 , Sarah E Palmer  2
Affiliations
Review

How to Define the Latent Reservoir: Tools of the Trade

Kirston M Barton et al. Curr HIV/AIDS Rep. 2016 Apr.

Abstract

HIV is a devastating worldwide epidemic that has had substantial social and economic impacts throughout the globe. Due to the presence of a small pool of latently infected cells that persists during antiretroviral therapy (ART), HIV is not curable. Because of the high cost of ART and the lack of reliable accessibility across the globe, life-long ART is unfortunately not a feasible solution for the epidemic. Therefore, new strategies need to be developed and implemented to address HIV-1 infection. Several approaches toward this end are currently under investigation (Ebina et al. in Sci Rep 3:2510, 2013; Archin et al. in Nature 487:482-5, 2012; Elliott et al. in PLoS Pathog 10:e1004473, 2014; Rasmussen et al. in Lancet HIV 1:e13-e21, 2014; Tebas et al. in N Engl J Med 370:901-10, 2014; Archin et al. in Nat Rev Microbiol 12:750-64, 2014; Barton et al. in PLoS One 9:e102684, 2014; Sogaard et al. in PLoS Pathog 11:e1005142, 2015). Initial studies have proven promising, but have highlighted the need for sensitive and accurate assays to detect changes in very low concentrations of virus to allow confident interpretation of the success of curative approaches. This review will focus on assays that are currently available and the advantages and limitations of each.

Keywords: HIV biomarkers; HIV pathogenesis; Human immunodeficiency virus; Latent HIV; Persistent HIV; Review; Single-copy assay; Viral outgrowth assay.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The many different stages of the HIV replication cycle and the response of the host’s immune system can be detected with sensitive assays to quantitate HIV in HIV-infected individuals on effective long-term antiretroviral therapy
See this image and copyright information in PMC

References

    1. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5(5):512–7. doi: 10.1038/8394. - DOI - PubMed
    1. McMahon JH, Elliott JH, Roney J, Hagenauer M, Lewin SR. Experiences and expectations of participants completing an HIV cure focused clinical trial. Aids. 2015;29(2):248–50. doi: 10.1097/QAD.0000000000000534. - DOI - PMC - PubMed
    1. Ebina H, Misawa N, Kanemura Y, Koyanagi Y. Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep. 2013;3:2510. doi:10.1038/srep02510. - PMC - PubMed
    1. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012;487(7408):482–5. doi:10.1038/nature11286. - PMC - PubMed
    1. Elliott JH, Wightman F, Solomon A, Ghneim K, Ahlers J, Cameron MJ, et al. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog. 2014;10(10):e1004473. doi:10.1371/journal.ppat.1004473. First clinical trial conducted using vorinostat that showed viral reactivation following administration. - PMC - PubMed

Publication types